181 related articles for article (PubMed ID: 38442462)
1. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
Sener S; Cam V; Ozen S; Batu ED
Semin Arthritis Rheum; 2024 Jun; 66():152426. PubMed ID: 38442462
[TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
[TBL] [Abstract][Full Text] [Related]
3. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
Yu Z; Wang L; Quan M; Zhang T; Song H
Rheumatology (Oxford); 2021 Apr; 60(4):1700-1707. PubMed ID: 33024992
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease.
Harada H; Shoda H; Tsuchiya H; Misaki M; Sawada T; Fujio K
Rheumatol Int; 2024 May; 44(5):961-971. PubMed ID: 38456909
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
[TBL] [Abstract][Full Text] [Related]
6. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review.
Paik JJ; Lubin G; Gromatzky A; Mudd PN; Ponda MP; Christopher-Stine L
Clin Exp Rheumatol; 2023 Mar; 41(2):348-358. PubMed ID: 35766013
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.
Ll Wilkinson MG; Deakin CT; Papadopoulou C; Eleftheriou D; Wedderburn LR
Pediatr Rheumatol Online J; 2021 Sep; 19(1):146. PubMed ID: 34563217
[TBL] [Abstract][Full Text] [Related]
8. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
Chen CY; Chen WC; Hsu CK; Chao CM; Lai CC
Int Immunopharmacol; 2021 Oct; 99():108027. PubMed ID: 34343937
[TBL] [Abstract][Full Text] [Related]
11. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
Dhir B; Meena SK; Sardana K; Sharath S
Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.
Heidari A; Ghane Y; Heidari N; Sadeghi S; Goodarzi A
Int Immunopharmacol; 2024 Jan; 127():111435. PubMed ID: 38150881
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Taylor PC
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
[TBL] [Abstract][Full Text] [Related]
16. Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis.
Kim H
Expert Rev Clin Immunol; 2024 Jun; 20(6):589-602. PubMed ID: 38299575
[TBL] [Abstract][Full Text] [Related]
17. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Chen M; Dai SM
Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
[TBL] [Abstract][Full Text] [Related]
18. JAK inhibitors in chronic plaque psoriasis: What is known so far.
Plachouri KM; Georgiou S
Drugs Today (Barc); 2020 Feb; 56(2):151-163. PubMed ID: 32163530
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R
Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]